Get the Stockscreener App
32.45
1.41%
0.365
Agios Pharmaceuticals Inc stock is traded at $32.45, with a volume of 767.84K.
It is up +1.41% in the last 24 hours and up +8.11% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$32.09
Open:
$32.29
24h Volume:
767.84K
Relative Volume:
1.25
Market Cap:
$1.88B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.857
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+9.20%
1M Performance:
+8.11%
6M Performance:
-44.72%
1Y Performance:
-10.45%
1-Day Range:
$32.28
$33.69
1-Week Range:
$29.70
$33.69
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
32.46 | 1.75B | 32.87M | 674.31M | -330.11M | 11.36 |
|
ONC
Beone Medicines Ltd Adr
|
244.81 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.66 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.40 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.38 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
496.67 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Nuveen Asset Management LLC Cuts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Ameriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 | AGIO Stock News - GuruFocus
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - The Manila Times
Agios Pharmaceuticals Showcases Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
BNP Paribas Financial Markets Sells 2,242 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is Zacks Research’s Estimate for AGIO Q2 Earnings? - Defense World
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook By Investing.com - Investing.com South Africa
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook - Investing.com Canada
Bank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Sell Rating by StockNews.com - Defense World
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Update Their Estimates For Agios Pharmaceuticals Inc - Stocksregister
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities - The Globe and Mail
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Sickle cell disease Market: Epidemiology, Therapies, - openPR.com
Agios Pharmaceuticals at Bank of America 2025 Healthcare Conference: Strategic Pipeline Advances - Investing.com Canada
Agios to Highlight Pyruvate Kinase Activation Portfolio with New - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 20 - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 2025 | AGIO Stock News - GuruFocus
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - The Manila Times
New Phase 3 Trial Data: Agios Blood Disorder Treatment Shows Promise in Children and Adults with Rare Diseases - Stock Titan
Northern Trust Corp Purchases 5,372 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Cantor Fitzgerald maintains AGIOS stock with Overweight rating By Investing.com - Investing.com Canada
Top-line data from Phase 3 trial of mitapivat expected this year - Sickle Cell Disease News
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.00 - Defense World
Trading (AGIO) With Integrated Risk Controls - news.stocktradersdaily.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.com - Defense World
Agios to Present at the 2025 RBC Capital Markets Global Healthca - GuruFocus
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire
Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com
Scotiabank Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - Defense World
Envestnet Asset Management Inc. Boosts Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank Analyst | AGIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOUSE JACQUALYN A | Director |
Apr 10 '25 |
Sale |
25.90 |
7,497 |
194,172 |
149,220 |
1.76%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):